Premium
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up
Author(s) -
Hotho D. M.,
de Bruijne J.,
Spaan M.,
Treitel M. A.,
Boonstra A.,
de Knegt R. J.,
Janssen H. L. A.,
Reesink H. W.
Publication year - 2013
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12012
Subject(s) - ribavirin , medicine , protease inhibitor (pharmacology) , virology , rescue therapy , combination therapy , viral load , hepatitis c virus , virus , antiretroviral therapy
Summary Achievement of a sustained virologic response ( SVR ) after peginterferon ( PEG ‐ IFN ) and ribavirin ( RBV ) treatment is considered to be a marker for the cure of chronic hepatitis C virus ( HCV ) infection. Long‐term follow‐up of patients with SVR after treatment with a direct acting antiviral has not yet been described. We used a randomized placebo‐controlled, double‐blind, two‐period phase 1b trial that was conducted in 40 HCV genotype 1 (treatment‐naïve and treatment‐experienced)‐infected patients. Nineteen patients achieved SVR after treatment with the HCV protease inhibitor narlaprevir followed by PEG ‐ IFN / RBV . In these patients, HCV ‐ RNA tests were scheduled at 3, 6, 12 and 24 months after end of treatment. Patients were followed for a median of 27 months (range 15–32) after end of treatment with a median number of follow‐up visits of 4 (range 3–8). All patients remained HCV ‐ RNA negative over time. SVR achieved following narlaprevir and PEG ‐ IFN / RBV ‐therapy was durable up to 32 months after the end of treatment.